Advertisement

Medical Oncology

, 33:34 | Cite as

Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables

  • Semra PaydasEmail author
  • Arbil Acikalin
  • Melek Ergin
  • Hikmet Celik
  • Basak Yavuz
  • Kahraman Tanriverdi
Original Paper

Abstract

miRNAs are small RNAs and control the expression of protein-encoding genes. The aim of this study was to determine the association between miRNA profile and clinical variables including age, stage, B symptom, histopathologic subtype, response to treatment, disease-free survival (DFS) and overall survival (OS) in classical Hodgkin lymphoma (cHL). A total of 377 miRNAs were studied by qPCR in 32 cases with cHL, and results were compared with 60 samples taken from cases with reactive lymphadenopathy. Biogazelle qbasePLUS 2.0 software was used to analyze the results. miR-582-3p, miR-525-3p, miR-448, miR-512-3p, miR-642a-5p, miR-876-5p, miR-532-3p, miR-654-5p, miR-128, miR-145-5p, miR-15b-5p, miR-328 and miR-660-5p were found to be decreased in cHL compared with controls. In contrast, miR-34a-5p (2.626-fold), miR-146a-5p (4.32-fold), miR-93-5p (2.347-fold), miR-20a-5p (4.930-fold), miR-339-3p (4.948-fold), miR-324-3p (4.98-fold), miR-372 (7.038-fold), miR-127-3p (8.234-fold), miR-155-5p (4.947-fold), miR-320a (17.502-fold) and miR-370 (21.479-fold) (p < 0.05) were found to be increased in cHL. There was no difference in miRNA profile according to the age, sex, stage, response to treatment, DFS and OS. However, miR-889 was found to be increased in patients with B symptom and miR-127-3p was found to be increased in nodular sclerosing subtype. Some miRNAs increase and some decrease in cHL. However, there was no clinical association between clinical variables and with the majority of the miRNA profile studied in this study. miR-889 and miR-127-3p were related to B symptom and nodular sclerosis subtype, respectively. We need more studies evaluating miRNA profile and clinical outcome in Hodgkin Lymphoma.

Keywords

Hodgkin lymphoma Subtype miRNA Prognosis Clinicopathological correlation Survival qPCR B symptom 

Notes

Acknowledgments

This study has been supported by Turkish Society of Hematology.

Author contributions

Semra Paydas contributed to study design, clinical management of the patients, paper writing and last control. Arbil Acikalin-Melek Ergin contributed to histopathologic examinations and re-evaluations of the biopsy samples; Hikmet Celik-Basak Yavuz did PCR analyses; Kahraman Tanriverdi contributed to coordination of all laboratory studies and statistical analyses.

Compliance with ethical standards

Conflict of interest

There is no conflict of interest.

Ethical standard

This study has been approved by the ethics committee.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Healy NA, Heneghan NA, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131:2215–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437–47.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMedGoogle Scholar
  5. 5.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S, Cho WC. Serum microRNA expression profiling predict response to RCHOP treatment indiffuse large B cell lymphoma patients. Ann Hematol. 2014;93:1735–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMedGoogle Scholar
  8. 8.
    Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251:499–505.CrossRefPubMedGoogle Scholar
  9. 9.
    Ansell Stephen M. Hodgkin lymphoma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:772–9.CrossRefGoogle Scholar
  10. 10.
    Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Möller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11:167–76.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207:243–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P, Lambein K, Vandesompele J, Van Roy N, Verhasselt B, Poppe B, Speleman F. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol. 2009;147:686–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LHC, Chadburn A, Tuschl T, Knowles DM, Tam W. MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173:242–52.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M. Regulation of JAK2 bymiR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114:2945–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alves FJ, Canales M, Estevez M, Menarguez J, Sabin P, Ruiz-Marcellan MC, Lopez A, Sanchez-Godoy P, Burgos F, Santonja C, Lopez J, Piris MA, Garcia JF. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013;162:336–47.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Semra Paydas
    • 1
    Email author
  • Arbil Acikalin
    • 2
  • Melek Ergin
    • 2
  • Hikmet Celik
    • 3
  • Basak Yavuz
    • 3
  • Kahraman Tanriverdi
    • 4
  1. 1.Department of Medical Oncology, Faculty of MedicineCukurova UniversityAdanaTurkey
  2. 2.Department of Pathology, Faculty of MedicineCukurova UniversityAdanaTurkey
  3. 3.TorosGen Biotechnology, TechnoscopeMersin UniversityMersinTurkey
  4. 4.Department of BiochemistryMassachusetts General HospitalBostonUSA

Personalised recommendations